Novo Nordisk shares surge on results of new obesity drug trial
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share price on Friday. View on euronews
OFF
Novo Nordisk Shares Surge On Results Of New Obesity Drug Trial
3 weeks from now
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share price on Friday. View on euronews
msn.com
OFF
Novo Nordisk Shares Surge On New Obesity Drug Results
3 weeks from now
Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial.
wsj.com
OFF
Novo Shares Soar As Experimental Shot Shows 22% Weight Loss
3 weeks from now
Jan 24, 2025 · Novo Nordisk A/S rose the most since August 2023 after its experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the …
bloomberg.com
OFF
Novo Nordisk Shares Surge On New Obesity Drug Results
3 weeks from now
Jan 24, 2025 · Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot showed patients lost 22% of their bodyweight in a clinical trial. …
morningstar.com
OFF
Novo Nordisk's Next-gen Obesity Treatment Hits Target In Early Study
3 weeks from now
Jan 24, 2025 · Novo said that patients on a high dose of the injectable form of the drug, called amycretin, lost 22% of their weight after 36 weeks, when analyzing the effects if all people …
statnews.com
OFF
Novo Valuation Surpasses Tesla On Experimental Obesity Drug Data
3 weeks from now
Mar 7, 2024 · Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously, after it told investors a Phase …
yahoo.com
OFF
Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms
3 weeks from now
Jan 24, 2025 · Shares of other weight-loss players diverged on Novo Nordisk's news. Lilly stock rose 2.5% to 785.41, while Viking Therapeutics ( VKTX ) shares yo-yoed and eventually …
investors.com
OFF
Novo Nordisk Stock Pops On Phase I Data For New Weight-loss …
3 weeks from now
Jan 24, 2025 · Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, …
yahoo.com
OFF
Novo Nordisk Shares Surge On New Obesity Drug Results — Update
3 weeks from now
Jan 24, 2025 · Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a …
morningstar.com
OFF
Novo Nordisk Shares Surge After Early Trial Shows New Obesity …
3 weeks from now
Novo Nordisk said a Phase 1 trial of its Amycretin treatment showed weight loss of around 13% after 12 weeks, better than the 6% weight loss patients experienced after 12 weeks in a …
msn.com
OFF
Novo Nordisk Hits All-time High As Oral Obesity Drug Shows …
3 weeks from now
Mar 7, 2024 · Wegovy (semaglutide), Novo Nordisk's highly popular GLP-1 obesity drug, helped patients shed around 6% after 12 weeks. Novo's ( NVO ) shares rose up to 7.5% to …
seekingalpha.com
OFF
Novo Shares Climb On Early Data For Dual-acting Obesity Drug
3 weeks from now
Jan 24, 2025 · Dive Brief: An experimental obesity drug from Novo Nordisk helped people lose an average of up to 22% of their body weight over 36 weeks in an early-stage trial, results that, if …
biopharmadive.com
OFF
Novo Nordisk Shares Surge On Results Of New Obesity Drug Trial
3 weeks from now
4 days ago · Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share price on Friday.
euronews.com
OFF
Novo Nordisk Leaps On New Obesity Drug Data | Pharmaphorum
3 weeks from now
Jan 24, 2025 · Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. …
pharmaphorum.com
OFF
Why Novo Nordisk Surged 14% On New Weight-loss Drug Results
3 weeks from now
Jan 24, 2025 · Novo Nordisk reports 22% average weight reduction in trial for its amycretin obesity drug. Shares of Novo Nordisk surged by close to 14%, while Eli Lilly dipped by about …
invezz.com
OFF
Novo Nordisk Shares Plunge After CagriSema Obesity Drug Trial ...
3 weeks from now
Dec 20, 2024 · Novo's shares fell as much as 27% after the results were announced, hitting their lowest since August 2023 in one of the biggest one-day wipeouts on record for a European …
investing.com
FAQs about Novo Nordisk shares surge on results of new obesity drug trial Coupon?
Why did Novo Nordisk stock rise premarket?
Does Novo Nordisk have a new weight-loss drug?
Does Novo Nordisk's oral semaglutide help you lose weight?
Why did Novo Nordisk stock jump Friday?
Is Novo Nordisk a good stock to buy?
Did Novo Nordisk lose $125 billion in cagrisema trial?
Install CouponFollow Extension on Chrome
Install the CouponFollow extension to search for discount codes when shopping the fastest!
Install CouponFollow Chrome Extension
Listing Store by Characters
